Inflammation modifies the pattern and the function of Toll-like receptors expressed by human mesenchymal stromal cells

Human Immunology

Volumn 71, Issue 3, 2010, Pages 235-244

  Raicevic, Gordana ^a   Rouas, Redouane ^a   Najar, Mehdi ^a   Stordeur, Patrick ^b   Id Boufker, Hicham ^a   Bron, Dominique ^a   Martiat, Philippe ^a   Goldman, Michel ^c   Nevessignsky, Michel T ^b   Lagneaux, Laurence ^a  

^a JULES BORDET INSTITUTE   (Belgium)

^b ERASME HOSPITAL   (Belgium)

^c UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

Allogeneic reaction; Immunomodulation; Inflammation; Mesenchymal stromal cells; Toll like receptors

Indexed keywords

CYTOKINE; INTERLEUKIN 12P35; INTERLEUKIN 1BETA; INTERLEUKIN 23P19; INTERLEUKIN 27P28; INTERLEUKIN 6; MESSENGER RNA; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 10; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CELL FATE; CELL FUNCTION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; INFLAMMATION; MALE; MESENCHYME CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; STROMA CELL; UPREGULATION;

EID: 76949094176     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humimm.2009.12.005     Document Type: Article

References (65)

1. Pittenger M.F., Mackay A.M., Beck S.C., Jaiswal R.K., Douglas R., Mosca J.D., et al. Multilineage potential of adult human mesenchymal stem cells. Science 284 (1999) 143-147
2. Krampera M., Pasini A., Pizzolo G., Cosmi L., Romagnani S., and Annunziato F. Regenerative and immunomodulatory potential of mesenchymal stem cells. Curr Opin Pharmacol 6 (2006) 435-441
3. Lee R.H., Kim B., Choi I., Kim H., Choi H.S., Suh K., et al. Characterization and expression analysis of mesenchymal stem cells from human bone marrow and adipose tissue. Cell Physiol Biochem 14 (2004) 311-324
4. Erices A., Conget P., and Minguell J.J. Mesenchymal progenitor cells in human umbilical cord blood. Br J Haematol 109 (2000) 235-242
5. in 't Anker P.S., Noort W.A., Scherjon S.A., Kleijburg-van der Keur C., Kruisselbrink A.B., van Bezooijen R.L., et al. Mesenchymal stem cells in human second-trimester bone marrow, liver, lung, and spleen exhibit a similar immunophenotype but a heterogeneous multilineage differentiation potential. Haematologica 88 (2003) 845-852
6. Haynesworth S.E., Baber M.A., and Caplan A.I. Cell surface antigens on human marrow-derived mesenchymal cells are detected by monoclonal antibodies. Bone 13 (1992) 69-80
7. Conget P.A., and Minguell J.J. Phenotypical and functional properties of human bone marrow mesenchymal progenitor cells. J Cell Physiol 181 (1999) 67-73
8. Sordi V., Malosio M.L., Marchesi F., Mercalli A., Melzi R., Giordano T., et al. Bone marrow mesenchymal stem cells express a restricted set of functionally active chemokine receptors capable of promoting migration to pancreatic islets. Blood 106 (2005) 419-427
9. Le Blanc K., Tammik C., Rosendahl K., Zetterberg E., and Ringden O. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol 31 (2003) 890-896
10. Reyes M., Lund T., Lenvik T., Aguiar D., Koodie L., and Verfaillie C.M. Purification and ex vivo expansion of postnatal human marrow mesodermal progenitor cells. Blood 98 (2001) 2615-2625
11. Caplan A.I., and Dennis J.E. Mesenchymal stem cells as trophic mediators. J Cell Biochem 98 (2006) 1076-1084
12. Le Blanc K., Frassoni F., Ball L., Locatelli F., Roelofs H., Lewis I., et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: A phase II study. Lancet 371 (2008) 1579-1586
13. Najar M., Rouas R., Raicevic G., Id B.H., Lewalle P., Meuleman N., et al. Mesenchymal stromal cells promote or suppress the proliferation of T lymphocytes from cord blood and peripheral blood: The importance of low cell ratio and role of interleukin-6. Cytotherapy 11 (2009) 570-583
14. Bartholomew A., Sturgeon C., Siatskas M., Ferrer K., McIntosh K., Patil S., et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 30 (2002) 42-48
15. Maitra B., Szekely E., Gjini K., Laughlin M.J., Dennis J., Haynesworth S.E., et al. Human mesenchymal stem cells support unrelated donor hematopoietic stem cells and suppress T-cell activation. Bone Marrow Transplant 33 (2004) 597-604
16. Krampera M., Glennie S., Dyson J., Scott D., Laylor R., Simpson E., et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 101 (2003) 3722-3729
17. Potian J.A., Aviv H., Ponzio N.M., Harrison J.S., and Rameshwar P. Veto-like activity of mesenchymal stem cells: functional discrimination between cellular responses to alloantigens and recall antigens. J Immunol 171 (2003) 3426-3434
18. Di Nicola M., Carlo-Stella C., Magni M., Milanesi M., Longoni P.D., Matteucci P., et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99 (2002) 3838-3843
19. Le Blanc K., Tammik L., Sundberg B., Haynesworth S.E., and Ringden O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 57 (2003) 11-20
20. Liotta F., Angeli R., Cosmi L., Fili L., Manuelli C., Frosali F., et al. Toll-like receptors 3 and 4 are expressed by human bone marrow-derived mesenchymal stem cells and can inhibit their T-cell modulatory activity by impairing Notch signaling. Stem Cells 26 (2008) 279-289
21. + T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica 90 (2005) 516-525
22. Krampera M., Cosmi L., Angeli R., Pasini A., Liotta F., Andreini A., et al. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 24 (2006) 386-398
23. Sotiropoulou P.A., Perez S.A., Gritzapis A.D., Baxevanis C.N., and Papamichail M. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells 24 (2006) 74-85
24. Spaggiari G.M., Capobianco A., Abdelrazik H., Becchetti F., Mingari M.C., and Moretta L. Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: Role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood 111 (2008) 1327-1333
25. Corcione A., Benvenuto F., Ferretti E., Giunti D., Cappiello V., Cazzanti F., et al. Human mesenchymal stem cells modulate B-cell functions. Blood 107 (2006) 367-372
26. Jiang X.X., Zhang Y., Liu B., Zhang S.X., Wu Y., Yu X.D., et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 105 (2005) 4120-4126
27. Aggarwal S., and Pittenger M.F. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105 (2005) 1815-1822
28. Meisel R., Zibert A., Laryea M., Gobel U., Daubener W., and Dilloo D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 103 (2004) 4619-4621
29. Roelen D.L., van der Mast B.J., in't Anker P.S., Kleijburg C., Eikmans M., van Beelen E., et al. Differential immunomodulatory effects of fetal versus maternal multipotent stromal cells. Hum Immunol 70 (2009) 16-23
30. Plumas J., Chaperot L., Richard M.J., Molens J.P., Bensa J.C., and Favrot M.C. Mesenchymal stem cells induce apoptosis of activated T cells. Leukemia 19 (2005) 1597-1604
31. Rizzo R., Campioni D., Stignani M., Melchiorri L., Bagnara G.P., Bonsi L., et al. A functional role for soluble HLA-G antigens in immune modulation mediated by mesenchymal stromal cells. Cytotherapy 10 (2008) 364-375
32. Muzio M., Bosisio D., Polentarutti N., D'Amico G., Stoppacciaro A., Mancinelli R., et al. Differential expression and regulation of Toll-like receptors (TLR) in human leukocytes: Selective expression of TLR3 in dendritic cells. J Immunol 164 (2000) 5998-6004
33. Hoebe K., Janssen E., and Beutler B. The interface between innate and adaptive immunity. Nat Immunol 5 (2004) 971-974
34. Cook D.N., Pisetsky D.S., and Schwartz D.A. Toll-like receptors in the pathogenesis of human disease. Nat Immunol 5 (2004) 975-979
35. Hwa C.H., Bae Y.C., and Jung J.S. Role of Toll-like receptors on human adipose-derived stromal cells. Stem Cells 24 (2006) 2744-2752
36. Meuleman N., Tondreau T., Ahmad I., Kwan J., Crokaert F., Delforge A., et al. Infusion of mesenchymal stromal cells can aid hematopoietic recovery following allogeneic hematopoietic stem cell myeloablative transplant: A pilot study. Stem Cells Dev 18 (2009) 1247-1252
37. Koc O.N., Day J., Nieder M., Gerson S.L., Lazarus H.M., and Krivit W. Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH). Bone Marrow Transplant 30 (2002) 215-222
38. Lazarus H.M., Koc O.N., Devine S.M., Curtin P., Maziarz R.T., Holland H.K., et al. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant 11 (2005) 389-398
39. Tondreau T., Lagneaux L., Dejeneffe M., Delforge A., Massy M., Mortier C., et al. Isolation of BM mesenchymal stem cells by plastic adhesion or negative selection: Phenotype, proliferation kinetics and differentiation potential. Cytotherapy 6 (2004) 372-379
40. Meuleman N., Tondreau T., Delforge A., Dejeneffe M., Massy M., Libertalis M., et al. Human marrow mesenchymal stem cell culture: Serum-free medium allows better expansion than classical alpha-MEM medium. Eur J Haematol 76 (2006) 309-316
41. Schaefer T.M., Desouza K., Fahey J.V., Beagley K.W., and Wira C.R. Toll-like receptor (TLR) expression and TLR-mediated cytokine/chemokine production by human uterine epithelial cells. Immunology 112 (2004) 428-436
42. St. Onge M., Dumas A., Michaud A., Laflamme C., Dussault A.A., and Pouliot M. Impact of anti-inflammatory agents on the gene expression profile of stimulated human neutrophils: Unraveling endogenous resolution pathways. PLoS ONE 4 (2009) e4902
43. Mailliard R.B., Wankowicz-Kalinska A., Cai Q., Wesa A., Hilkens C.M., Kapsenberg M.L., et al. alpha-type-1 polarized dendritic cells: A novel immunization tool with optimized CTL-inducing activity. Cancer Res 64 (2004) 5934-5937
44. Daxecker H., Raab M., Markovic S., Karimi A., Griesmacher A., and Mueller M.M. Endothelial adhesion molecule expression in an in vitro model of inflammation. Clin Chim Acta 325 (2002) 171-175
45. Stordeur P., Poulin L.F., Craciun L., Zhou L., Schandene L., de Lavareille A., et al. Cytokine mRNA quantification by real-time PCR. J Immunol Methods 259 (2002) 55-64
46. Nasef A., Chapel A., Mazurier C., Bouchet S., Lopez M., Mathieu N., et al. Identification of IL-10 and TGF-beta transcripts involved in the inhibition of T-lymphocyte proliferation during cell contact with human mesenchymal stem cells. Gene Expr 13 (2007) 217-226
47. Umezawa A., Harigaya K., Abe H., and Watanabe Y. Gap-junctional communication of bone marrow stromal cells is resistant to irradiation in vitro. Exp Hematol 18 (1990) 1002-1007
48. Bruhl P., Mergenthaler H.G., and Dormer P. Haemopoietic inductive capacity of irradiated stromal cell layers in human micro long-term bone marrow cultures. Cell Tissue Kinet 21 (1988) 411-417
49. Tomchuck S.L., Zwezdaryk K.J., Coffelt S.B., Waterman R.S., Danka E.S., and Scandurro A.B. Toll-like receptors on human mesenchymal stem cells drive their migration and immunomodulating responses. Stem Cells 26 (2008) 99-107
50. van den Berk LC, Jansen BJ, Siebers-Vermeulen KG, Netea MG, Latuhihin T, Bergevoet S, et al. Toll-like receptor triggering in cord blood mesenchymal stem cells. J Cell Mol Med, in press.
51. Opitz C.A., Litzenburger U.M., Lutz C., Lanz T.V., Tritschler I., Koppel A., et al. Toll-like receptor engagement enhances the immunosuppressive properties of human bone marrow-derived mesenchymal stem cells by inducing indoleamine-2,3-dioxygenase-1 via interferon-beta and protein kinase R. Stem Cells 27 (2009) 909-919
52. Reddy P., and Ferrara J.L. Immunobiology of acute graft-versus-host disease. Blood Rev 17 (2003) 187-194
53. Toungouz M., Denys C.H., De Groote D., Andrien M.E., and Dupont E.C. Alloactivation induced during mixed-lymphocyte reaction provokes release of tumor necrosis factor alpha and interleukin 6 by macrophages and primes them to lipopolysaccharides. Hum Immunol 38 (1993) 221-225
54. Cooke K.R., Gerbitz A., Crawford J.M., Teshima T., Hill G.R., Tesolin A., et al. LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation. J Clin Invest 107 (2001) 1581-1589
55. Feghali C.A., and Wright T.M. Cytokines in acute and chronic inflammation. Front Biosci 2 (1997) d12-d26
56. Romieu-Mourez R., Francois M., Boivin M.N., Bouchentouf M., Spaner D.E., and Galipeau J. Cytokine modulation of TLR expression and activation in mesenchymal stromal cells leads to a proinflammatory phenotype. J Immunol 182 (2009) 7963-7973
57. Goriely S., Neurath M.F., and Goldman M. How microorganisms tip the balance between interleukin-12 family members. Nat Rev Immunol 8 (2008) 81-86
58. Lankford C.S., and Frucht D.M. A unique role for IL-23 in promoting cellular immunity. J Leukoc Biol 73 (2003) 49-56
59. Voo K.S., Wang Y.H., Santori F.R., Boggiano C., Wang Y.H., Arima K., et al. Identification of IL-17-producing FOXP3+ regulatory T cells in humans. Proc Natl Acad Sci USA 106 (2009) 4793-4798
60. Chen Q., Ghilardi N., Wang H., Baker T., Xie M.H., Gurney A., et al. Development of Th1-type immune responses requires the type I cytokine receptor TCCR. Nature 407 (2000) 916-920
61. Takeda A., Hamano S., Yamanaka A., Hanada T., Ishibashi T., Mak T.W., et al. Cutting edge: Role of IL-27/WSX-1 signaling for induction of T-bet through activation of STAT1 during initial Th1 commitment. J Immunol 170 (2003) 4886-4890
62. Villarino A., Hibbert L., Lieberman L., Wilson E., Mak T., Yoshida H., et al. The IL-27R (WSX-1) is required to suppress T cell hyperactivity during infection. Immunity 19 (2003) 645-655
63. + T cells partially through STAT3-dependent mechanism. J Immunol 177 (2006) 5377-5385
64. Neufert C., Becker C., Wirtz S., Fantini M.C., Weigmann B., Galle P.R., et al. IL-27 controls the development of inducible regulatory T cells and Th17 cells via differential effects on STAT1. Eur J Immunol 37 (2007) 1809-1816
65. Pevsner-Fischer M., Morad V., Cohen-Sfady M., Rousso-Noori L., Zanin-Zhorov A., Cohen S., et al. Toll-like receptors and their ligands control mesenchymal stem cell functions. Blood 109 (2007) 1422-1432